Teleflex awarded Short Term Central Venous Catheters contract from Vizient

Including market leading Arrow™ CVCs and Arterial Catheters

WAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been awarded a contract by Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement, effective January 1, 2025, covers the supply of Teleflex’s Central Venous Access Catheters and Arterial Catheters.

Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 65% of the nation’s acute care providers. This includes 97% of the nation’s academic medical centers, and more than 35% of the acute care market. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than $140 billion in annual purchasing volume to improve patient outcomes and lower costs. Through this agreement, Vizient provider-customers will now gain access to increased savings and pre-negotiated terms on Teleflex’s vascular access products.

“As the market leader in both Central Venous Catheters (CVCs)¹ and Arterials², we are pleased to offer Vizient provider-customers one of the broadest portfolios of vascular access products,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular. “Arrow™ Vascular Access Products are designed to equally benefit clinicians and patients, help protect against vascular access related complications like infection, thrombosis, and tip malposition, and help clinicians follow independent third-party vascular access guidelines^{3-6, 8-13}.”

For more than four decades, Teleflex, through its Arrow™ Catheters has been at the forefront of vascular access innovation. The Arrowg+ard Blue Plus™ CVCs feature broad-spectrum antimicrobial protection against fungi, gram-positive, and gram-negative bacteria, reducing Central Line-Associated Bloodstream Infections (CLABSI) by 67-100%^3-6.

The Catheter-Related Bloodstream Infection (CRBSI) risk rates for Arterial Catheters and short-term CVCs have been shown to be comparable, indicating that Arterials should receive the same precautions for catheter insertion and care.⁷ Arrow™ Arterial Catheterization Kits provide the essential tools and safety features in an all-inclusive kit—with a layout that is intuitive and easy to use.

The contract includes access to a range of products, including:

• Arrowg+ard Blue Plus™ CVCs
• Arrow™ ErgoPack™ Complete Systems
• Arrow™ Arterial Catheters and Catheterization Kits

These solutions help healthcare systems:

• Comply with practice recommendations including: CDC Recommendations, SHEA Guidelines, INS Standards of Practice and OSHA Bloodborne Pathogens Standard^8-11
• Standardize vascular access products across a healthcare system
• Maintain a high standard of patient care
• Control costs and risks from infections^{3-6, 12}

To learn more about Arrow™ Antimicrobial Catheter and Kitting Solutions, visit our website.

About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

References

1. IQIVA Data. Data based on 2024 Q3 Total Acute CVC market unit share for Teleflex. 2024.
2. IQVIA Data. Data based on 2024 Q3 Total Arterial market unit share for Teleflex. 2024.
3. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a Second-Generation Venous Catheter Impregnated with Chlorhexidine and Silver Sulfadiazine of Central Catheter-Related Infections. Ann Intern Medicine. 2005; 143: 570-80. Sponsored by Arrow (Teleflex).
4. Lorente L, Lecuona M, Jimenez A, et al. Chlorhexidine-silver sulfadiazine-impregnated venous catheters save costs. American Journal of Infection Control. 2014; 42: 321-4.
5. Lorente L, Lecuona M, Jimenez A, et al. Cost/benefit analysis of chlorhexidine-silver sulfadiazine-impregnated venous catheters for femoral access. American Journal of Infection Control. 2014; 42: 1130-2.
6. Lorente, L, et al. Chlorhexidine-silver sulfadiazine-impregnated venous catheters are efficient even at subclavian sites without tracheostomy. American journal of infection control. 2016; 44(12): 1526-29. Zimlichman, E, et al.
7. Lucet et al. Infectious risk associated with arterial catheters compared to central venous catheters. Society of Critical Care Medicine. 2010 Vol.38, No. 4.
8. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011 (Revised 2017). 2. Atlanta, GA: Centers for Disease Control and Prevention; 2017.
9. Buetti, N., Marschall, J., Drees, M., Fakih, M., Hadaway, L., Maragakis, L., Mermel, L. (2022). Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infection Control & Hospital Epidemiology, 1-17. doi:10.1017/ice.2022.87.
10. Nickel B, Gorski LA, Kleidon TM, et al. Infusion therapy standards of practice. J InfusNurs. 2024;47(suppl1):S1-S285.
11. Occupational Safety & Health Administration Regulations (Standards – 29 CFR). Part 1910.1030: Bloodborne pathogens. Occupational Safety & Health Administration Web site. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030. Accessed on February 12, 2020.
12. Abouleish, YZ, Oldfield EC, Marik PE. Comparison of central-line–associated bloodstream infections between central venous catheters lined by combined chlorhexidine and silver sulfadiazine versus silver ionotrophes alone: A before–after–before retrospective study. Infection Control & Hospital Epidemiology (2020): 1-3.
13. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus: AVAR-000427. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

Rx only
Contraindication: The Arrowg+ard Blue Plus^™ CVC is contraindicated for patients with known hypersensitivity to chlorhexidine and silver sulfadiazine and/or sulfa drugs.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Plus, Barrigel, Deknatel, ErgoPack, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2025 Teleflex Incorporated. All rights reserved. MC-010372

Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836